Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Cornberg

Showing results (221-230 of 350) with videos related to

Pageof 35
Sort By:
Hepatology (Baltimore, Md.)|October 23, 2016
Antiviral treatment and liver-related complications in hepatitis deltaAnika Wranke, Beatriz Calle Serrano, Benjamin Heidrich, et al.
Hepatology (Baltimore, Md.)|February 4, 2020
MAIT Cells Are Enriched and Highly Functional in Ascites of Patients With Decompensated Liver CirrhosisChristian E Niehaus, Benedikt Strunz, Martin Cornillet, et al.
Journal of Viral Hepatitis|March 31, 2022
Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in GermanyTammo L Tergast, Sarah Blach, Frank Tacke, et al.
Metabolic Brain Disease|December 10, 2024
Value of systemic inflammation markers for the detection of minimal and prediction of overt hepatic encephalopathy after TIPS insertionAnja Tiede, Lena Stockhoff, Alena F Ehrenbauer, et al.
Scandinavian Journal of Gastroenterology|July 31, 2019
The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patientsFreya Wellhöner, Nico Döscher, Tammo Lambert Tergast, et al.
Journal of Hepatology|September 24, 2022
Reverse inflammaging: Long-term effects of HCV cure on biological ageCarlos Oltmanns, Zhaoli Liu, Jasmin Mischke, et al.
British Journal of Clinical Pharmacology|January 19, 2018
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medicationsFiona Marra, Christoph Höner Zu Siederdissen, Saye Khoo, et al.
Journal of Viral Hepatitis|May 18, 2021
Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R)Valerie Ohlendorf, Arne Schäfer, Stefan Christensen, et al.
The Journal of Infectious Diseases|November 3, 2016
The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T CellsThomas Schirdewahn, Jan Grabowski, Solomon Owusu Sekyere, et al.
Alimentary Pharmacology & Therapeutics|November 10, 2022
Application of CT contrast medium is not associated with an increased risk for acute kidney injury in patients with decompensated cirrhosisTammo L Tergast, Benjamin Schulte, Marie Griemsmann, et al.
Pageof 35

Showing results (221-230 of 350) with videos related to

Sort By:
Pageof 35
Hepatology (Baltimore, Md.)|October 23, 2016
Antiviral treatment and liver-related complications in hepatitis deltaAnika Wranke, Beatriz Calle Serrano, Benjamin Heidrich, et al.
Hepatology (Baltimore, Md.)|February 4, 2020
MAIT Cells Are Enriched and Highly Functional in Ascites of Patients With Decompensated Liver CirrhosisChristian E Niehaus, Benedikt Strunz, Martin Cornillet, et al.
Journal of Viral Hepatitis|March 31, 2022
Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in GermanyTammo L Tergast, Sarah Blach, Frank Tacke, et al.
Metabolic Brain Disease|December 10, 2024
Value of systemic inflammation markers for the detection of minimal and prediction of overt hepatic encephalopathy after TIPS insertionAnja Tiede, Lena Stockhoff, Alena F Ehrenbauer, et al.
Scandinavian Journal of Gastroenterology|July 31, 2019
The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patientsFreya Wellhöner, Nico Döscher, Tammo Lambert Tergast, et al.
Journal of Hepatology|September 24, 2022
Reverse inflammaging: Long-term effects of HCV cure on biological ageCarlos Oltmanns, Zhaoli Liu, Jasmin Mischke, et al.
British Journal of Clinical Pharmacology|January 19, 2018
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medicationsFiona Marra, Christoph Höner Zu Siederdissen, Saye Khoo, et al.
Journal of Viral Hepatitis|May 18, 2021
Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R)Valerie Ohlendorf, Arne Schäfer, Stefan Christensen, et al.
The Journal of Infectious Diseases|November 3, 2016
The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T CellsThomas Schirdewahn, Jan Grabowski, Solomon Owusu Sekyere, et al.
Alimentary Pharmacology & Therapeutics|November 10, 2022
Application of CT contrast medium is not associated with an increased risk for acute kidney injury in patients with decompensated cirrhosisTammo L Tergast, Benjamin Schulte, Marie Griemsmann, et al.
Pageof 35